Drug Profile
Esmolol - NovaLead Pharma
Alternative Names: Esmolol Hydrochloride; Galnobax; VLD-02Latest Information Update: 11 Nov 2022
Price :
$50
*
At a glance
- Originator NovaLead Pharma Pvt. Ltd
- Class Antiarrhythmics; Antihypertensives; Ethanolamines; Foot disorder therapies; Phenols; Propionates; Skin disorder therapies; Small molecules
- Mechanism of Action Beta 1 adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Diabetic foot ulcer
Highest Development Phases
- Phase III Diabetic foot ulcer
Most Recent Events
- 19 Sep 2022 Efficacy data from a phase III trial in Diabetic foot ulcer presented at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD-2022)
- 06 Dec 2021 NovaLead Pharma completes a phase III trial for Diabetic foot ulcer in India (NCT03998436)
- 06 Apr 2021 Phase III trial is still ongoing for Diabetic foot ulcer in India (NCT03998436)